Pharmesis International (SGX:BFK) Notes Receivable: S$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGX:BFK Pharmesis International Ltd SGX:BFK
31 GF Score
Price S$0.11
GF Value S$0.09
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Pharmesis International Notes Receivable?

Pharmesis International SGX:BFK 31 Notes Receivable is S$0.00 Mil as of Dec. 2025. GuruFocus rates SGX:BFK with a GF Score™ of 31/100 and a GF Value™ of S$0.09 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Pharmesis International's Notes Receivable for the quarter that ended in Dec. 2025 was S$0.00 Mil.

Pharmesis International Notes Receivable Related Terms

Pharmesis International Notes Receivable Historical Data

* Premium members only.

The historical data trend for Pharmesis International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmesis International Notes Receivable Chart

Pharmesis International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharmesis International Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SGX:BFK
31GF Score
Pharmesis International Ltd SGX:BFK
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmesis International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of S$0.00 Mil mean?
Pharmesis International (SGX:BFK) has a Notes Receivable of S$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmesis International and its competitors.
Is Pharmesis International's Notes Receivable too high?
Pharmesis International's current Notes Receivable is S$0.00 Mil. Overall, Pharmesis International has a GF Score™ of 31/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's Notes Receivable compare to ZTS and UTHR?
Pharmesis International's Notes Receivable of S$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pharmesis International and its competitors. Pharmesis International's current Notes Receivable is S$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Overvalued. The stock's GF Value™ is S$0.09, compared to a current price of S$0.11 — trading 18.9% above its estimated fair value. The current Notes Receivable is S$0.00 Mil. Pharmesis International's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current Notes Receivable is S$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmesis International (SGX:BFK) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmesis International stock appears to be overvalued. The current stock price of S$0.11 is trading 18.9% above its estimated GF Value™ of S$0.09. GuruFocus considers Pharmesis International to be Modestly Overvalued.

Key valuation signals for SGX:BFK:

  • Notes Receivable: S$0.00 Mil
  • GF Value™: S$0.09 vs. price of S$0.11 (18.9% above fair value)
  • GF Score™: 31/100 with 5 warning signs

No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmesis International Business Description

Address 5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
31GF Score

Get the complete analysis for SGX:BFK

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

S$0.11
Price
S$0.09
GF Value